| Execution period | Financial Year 2024-25 |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹731.70
- Market cap
- ₹11,517 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.5×Sector 45.9×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other other announcement announcements
All →Midwest Other Announcement
Midwest Ltd filed its quarterly shareholding pattern for the quarter ended 30 September 2026. Promoters hold 77.12% of equity; public holds 22.88%.
Rhetan TMT Other Announcement
Rhetan TMT filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31. Promoter and promoter group hold 62.12%, with no transaction or capital event described.
Yajur Fibres Other Announcement
Yajur Fibres Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026. The filing is routine SEBI Reg 31 disclosure with no transaction.
Polycon International Other Announcement
Polycon International's quarterly shareholding pattern for the period ending 30 September 2026, showing promoter and public holdings. This is routine SEBI Reg 31 compliance paperwork with no transaction or business event.
Abril Paper Tech Other Announcement
Abril Paper Tech appointed internal and secretarial auditors for FY 2026-27 at its 31 October 2026 board meeting. No monetary value was disclosed.
- Execution
- FY 2026-27
Haleos Labs Other Announcement
Haleos Labs withheld FY2025-26 dividend for shareholders who have not updated KYC or bank details. Notices were sent to affected shareholders on 31 October 2026 pending compliance.